Search Results

TAAA Stent Graft System Developed at Sanford Health Receives FDA Breakthrough Device Designation

October 19, 2021—Sanford Health announced that the investigational aortic stent graft system for the treatment of thoracoabdominal aortic aneurysms (TAAAs) designed by vascular surgeon Patrick Kelly, MD, has been granted Breakthrough Device designation by the FDA.

IDE Study Will Evaluate Physician-Developed TAAA Stent Graft

February 19, 2015—Sanford Health of Sioux Falls, South Dakota, announced that it has commenced enrollment in the Sanford Health Visceral Manifold Study for the repair of thoracoabdominal aortic aneurysms (TAAA) using an investigational device and procedure developed by Sanford Health’s Patrick Kelly, MD.

Medtronic to Collaborate With Sanford Health to Develop TAAA Stent Graft

April 14, 2015—Medtronic plc and Sanford Health, the South Dakota-based healthcare system, announced plans to develop a stent graft system for the endovascular treatment of thoracoabdominal aortic aneurysms (TAAAs) under an exclusive patent license agreement.

First Patient Treated in Study of Medtronic Valiant TAAA Stent Graft System

February 9, 2016—Medtronic plc and Sanford Health, one of the nation’s largest health care systems, announced the first patient enrolled in a clinical study using the Medtronic Valiant thoracoabdominal aortic aneurysm (TAAA) stent graft system.

FDA Approves Study of New Unitary Manifold Stent Graft System for TAAA

June 21, 2016—Sanford Vascular Innovations (SVI), a division of Sanford Health, announced US Food and Drug Administration approval to study a new device to treat complex aneurysms occurring in the descending aorta. Sanford Health is an integrated health system headquartered in the Fargo, North Dakota and Sioux Falls, South Dakota regions.

Sanford Health and University of South Dakota Collaborate to Develop DCBs With Precise Drug Delivery for PAD Treatment

December 16, 2015—Sanford Health and the University of South Dakota (USD) announced that they are collaborating to develop more effective drug-coated balloons (DCBs) to treat peripheral artery disease.

Liquet Versus New Catheter Configuration Cleared for Pulmonary Artery Pressure Measurement

February 24, 2026—Liquet Medical Inc. announced it has received a second FDA 510(k) clearance for a new configuration of its Versus catheter.